Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
Completed
UCB Pharma
Phase 1/Phase 2
2006-05-04
The purpose of the study is to determine the tolerability, the initial safety profile and
maximum tolerated dose, and to obtain preliminary information on the antitumor activity of
inotuzumab ozogamicin [CMC-544] in combination with rituximab in subjects with follicular,
diffuse large B-Cell, or mantle cell NHL.
Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
Completed
Pfizer
Phase 1/Phase 2
2006-05-04
The purpose of the study is to determine the tolerability, the initial safety profile and
maximum tolerated dose, and to obtain preliminary information on the antitumor activity of
inotuzumab ozogamicin [CMC-544] in combination with rituximab in subjects with follicular,
diffuse large B-Cell, or mantle cell NHL.
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
Terminated
UCB Pharma
Phase 3
2007-11-01
This protocol is designed to assess the efficacy and safety of inotuzumab ozogamicin given
with rituximab compared to a defined investigator's choice therapy. Subjects will be
randomized to one of these two arms of the study.
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
Terminated
Pfizer
Phase 3
2007-11-01
This protocol is designed to assess the efficacy and safety of inotuzumab ozogamicin given
with rituximab compared to a defined investigator's choice therapy. Subjects will be
randomized to one of these two arms of the study.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.